Africa CDC urges stronger Ebola exit screenings at member-state borders – CIDRAP

MONUSCO/Flickr cc
The Africa Centres for Disease Control and Prevention (Africa CDC) is urging member states to strengthen border exit screenings in light of the growing Ebola outbreak in the Democratic Republic of the Congo (DRC).
Analysis from the Africa CDC Emergency Consultative Group (ECG), an independent advisory body to the Africa CDC, said the 11 countries most at risk for Ebola and those bordering the DRC should enhance surveillance but not institute travel bans. 
Being prepared will reduce the risk of the virus spreading locally in the event of an imported case. 
“Being prepared will reduce the risk of the virus spreading locally in the event of an imported case. Preparedness builds confidence in the local response and reduces community anxiety and concern that often follows the discovery of an imported case of Ebola disease,” said Salim Abdool Karim, MBChB, PhD, chair of the ECG, in an Africa CDC press release. 
As of June 10 and 11, the US Centers for Disease Control and Prevention (US CDC) said the outbreak in the DRC and Uganda has grown to 695 confirmed cases, 138 deaths. All but 19 of those cases are from the DRC, where Ituri province is the epicenter of the outbreak. At least 23 people have recovered. 
The ECG formally supported the development of a diagnostic laboratory in Ituri and said there was an urgent need for Bundibugyo-specific rapid diagnostic tests to speed laboratory confirmation in affected and high-risk countries. 
This is only the fourth documented Ebola outbreak caused by the Bundibugyo strain and one of the reasons transmission went undetected for weeks because tests were looking for only the Zaire Ebolavirus. 
Earlier this week, Africa CDC received €11.5 million ($13.3 million) in a renewed commitment from the European Commission to support stronger preparedness and a coordinated response to the Ebola outbreak. Included is €5 million ($5.8 million) worth of testing equipment, including rapid diagnostic devices and lab test kits, to be deployed quickly where they are needed most.
Yesterday, the US Department of State announced an additional $20 million in funding to support comprehensive preparedness activities in countries surrounding the current outbreak, including Burundi, Kenya, Rwanda, and South Sudan. 
In scientific developments, Nature Medicine has a case report on Uganda’s index case of Bundibugyo Ebola. 
The man traveled from the DRC to Uganda and was admitted to a private hospital in Kampala on May 11 after more than two weeks of vomiting and diarrhea. Upon hospitalization, he deteriorated quickly, developed multiorgan failure, and died on May 14. 
Of the 19 cases in Uganda, 14 have been imported, and five have been among Ugandan nationals. 
And new findings of a longitudinal study in Liberia indicate that Ebola is associated with neurologic complications in survivors, with increased healthcare burden and socioeconomic costs. The neurologic issues generally improved with time, but some were long-term. The study, published in JAMA Neurology, included 148 Ebola survivors and 81 controls. 
The CDC also now reports 321 total confirmed cases.
Erica Stum was a mother, a teacher, and a cervical cancer advocate. An HPV vaccine could have saved her life (part 1 of 3).
The human papillomavirus (HPV) now causes more head and neck cancers than cervical cancers (part 2 of 3).
There are more reports of attacks on burial teams and healthcare workers.
The order directs the agency and a federal vaccine advisory board to align with an HHS assessment that calls for fewer childhood vaccines.
In a new Lancet study, researchers estimate the outbreak could be more than double current numbers.
The guidance illustrates the growing chasm between the medical organization and the federal health agency.
At least 515 cases have come from the DR Congo’s Ituri province. 
Infections in US animals rise to 6 amid increasing concerns of further spread.
Infections have been identified in New York, Maryland, and Virginia, with a death in Maryland.
Help make CIDRAP’s vital work possible
CIDRAP – Center for Infectious Disease Research & Policy
Research and Innovation Office, University of Minnesota, Minneapolis, MN
Email us
© 2026 Regents of the University of Minnesota. All rights Reserved.
The University of Minnesota is an equal opportunity educator and employer
Research and Innovation Office |   Contact U of M  |  Privacy Policy
Newsletter subscribe

source